Search

Displaying results 8221 - 8230 of 10000 in total
  1. Drug

    Pemvidutide

    go.drugbank.com/drugs/DB18998
    Investigational

    Pemvidutide is under investigation in clinical trial NCT05989711 (Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial)).

  2. Drug

    Mivelsiran

    go.drugbank.com/drugs/DB19003
    Investigational

    Mivelsiran is under investigation in clinical trial NCT06393712 (A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy).

  3. Drug

    Danburstotug

    go.drugbank.com/drugs/DB19064
    Investigational

    Danburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).

  4. Drug

    Fepixnebart

    go.drugbank.com/drugs/DB19079
    Investigational

    Fepixnebart is under investigation in clinical trial NCT04456686 (Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Osteoarthritis).

  5. Drug

    Renadirsen

    go.drugbank.com/drugs/DB19132
    Investigational

    Renadirsen is under investigation in clinical trial NCT04433234 (Long-term, Extension Study of Ds-5141b in Patients With Duchenne Muscular Dystrophy).

  6. Drug

    Emrusolmin

    go.drugbank.com/drugs/DB13927
    Investigational

    Emrusolmin restores hippocampal synaptic and transcriptional plasticity as well as spatial memory in a mouse model for Alzheimer's disease, when given orally before or after the onset of pathology.

  7. Drug

    PF-04995274

    go.drugbank.com/drugs/DB12675
    Investigational

    Pf 04995274 is under investigation in clinical trial NCT01193062 (Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274

  8. Drug

    Human growth hormone-releasing peptide 3

    go.drugbank.com/drugs/DB19227
    Investigational

    Human growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

  9. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

  10. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    [L15002, L15007] BNT162c2 is undergoing evaluation in clinical trials in both the USA (NCT04368728) and Germany (NCT04380701).[L15017, L15022] … [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.